This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CNAT vs. SCPS, EVLO, CMRA, ARDS, STAB, AMPE, CLVR, EFTR, HSTO, and MTEMShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and Molecular Templates (MTEM). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. Its Competitors Scopus BioPharma Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Clever Leaves eFFECTOR Therapeutics Histogen Molecular Templates Conatus Pharmaceuticals (NASDAQ:CNAT) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Which has higher valuation and earnings, CNAT or SCPS? Conatus Pharmaceuticals has higher revenue and earnings than Scopus BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConatus Pharmaceuticals$21.72M0.00-$11.39MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Which has more volatility and risk, CNAT or SCPS? Conatus Pharmaceuticals has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Does the media refer more to CNAT or SCPS? In the previous week, Conatus Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Conatus Pharmaceuticals Neutral Scopus BioPharma Neutral Is CNAT or SCPS more profitable? Scopus BioPharma has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Scopus BioPharma's return on equity of 0.00% beat Conatus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Conatus Pharmaceuticals-52.42% -48.22% -39.32% Scopus BioPharma N/A N/A N/A Do institutionals and insiders believe in CNAT or SCPS? 15.2% of Conatus Pharmaceuticals shares are held by institutional investors. 11.3% of Conatus Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryConatus Pharmaceuticals beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10K$784.70M$5.45B$8.93BDividend YieldN/A4.84%5.22%4.01%P/E Ratio0.001.3027.2420.06Price / Sales0.00230.50426.37117.54Price / CashN/A23.4426.2128.59Price / Book0.006.237.925.56Net Income-$11.39M-$27.94M$3.17B$248.56M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.00flatN/A-99.9%$10K$21.72M0.0030SCPSScopus BioPharmaN/A$0.00-97.0%N/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5K$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020AMPEAmpio Pharmaceuticals0.142 of 5 stars$0.00flatN/AN/A$3KN/A0.0020CLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.8%$1K$3.55M0.0010Gap DownHSTOHistogenN/A$0.00-25.0%N/A-99.9%$1K$19K0.0020MTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260 Related Companies and Tools Related Companies Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors Histogen Competitors Molecular Templates Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNAT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNAT Stock Alerts